Haemonetics Co. (NYSE:HAE) Stake Boosted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 1.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 992,229 shares of the medical instruments supplier's stock after buying an additional 10,990 shares during the period. Dimensional Fund Advisors LP owned 1.98% of Haemonetics worth $77,470,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HAE. Covestor Ltd increased its holdings in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after buying an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new position in Haemonetics in the fourth quarter worth approximately $62,000. Parkside Financial Bank & Trust increased its stake in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the last quarter. AlphaQuest LLC raised its position in Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after purchasing an additional 1,826 shares during the period. Finally, KBC Group NV lifted its stake in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 712 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities decreased their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Finally, StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $101.22.

Haemonetics Stock Up 0.0 %

Shares of HAE stock traded up $0.01 during mid-day trading on Monday, reaching $63.86. 36,862 shares of the company were exchanged, compared to its average volume of 689,374. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The company has a market capitalization of $3.21 billion, a P/E ratio of 25.21, a P/E/G ratio of 1.11 and a beta of 0.41. The business's 50 day simple moving average is $62.73 and its 200 day simple moving average is $71.69.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Research analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.